ClinicalTrials.gg
Not yet recruitingNCT07129499Updated Aug 19, 2025

Shenbai Granules for Preventing Malignant Transformation of High-risk Colorectal Adenomas

An interventional study of Shenbai Granules and Placebo in Colorectal Adenoma, High Risk and TCM, sponsored by Jiangsu Famous Medical Technology Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-19.

Sponsored by Jiangsu Famous Medical Technology Co., Ltd. · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Study summary

This multicenter, randomized, double-blind, placebo-controlled trial will enroll 450 patients with completely resected high-risk colorectal adenoma (HR-CRA), randomly assigned (1:1) to 6 months of Shenbai Granules (SBG) or placebo, followed for 3 years post-polypectomy. Primary endpoint: 3-year cumulative incidence of metachronous HR-CRA. Secondary endpoints: incidence, number, size, distribution, histology of low-risk adenomas and serrated lesions, and colorectal cancer occurrence.

Read the detailed description

High-risk colorectal adenomas (HR-CRAs) are a recognized precursor lesion for colorectal cancer, with 25-40% of patients developing metachronous adenomas within 3 years after endoscopic resection. Low-dose aspirin is the only agent supported by high-level evidence for reducing the incidence of metachronous HR-CRAs, but its use is limited by bleeding risks. Although previous studies on the traditional Chinese medicine compound Shenbai Granules (SBG) have suggested its potential in preventing metachronous HR-CRAs, sufficient evidence from randomised controlled trials (RCTs) is still lacking. This trial aims to confirm the efficacy and safety of SBG in preventing the development of metachronous adenomas and subsequent carcinogenesis, and to identify clinical predictors of treatment response to define the optimal target population. This multicentre, randomised, double-blind, placebo-controlled trial will enroll 450 patients with endoscopically resected HR-CRAs. Participants will be randomly allocated 1:1 to receive either SBG (n=225) or a matching placebo (n=225). The trial comprises a 14-day screening period, a 6-month treatment phase, and a 30-month surveillance phase, including four on-site visits and one telephone follow-up. The primary endpoint is the three-year cumulative incidence of metachronous HR-CRA. Secondary endpoints include the incidence of metachronous low-risk adenomas and serrated lesions within the same 3-year window, cumulative number and size of lesions, anatomic distribution, histopathology, and the incidence of colorectal cancer.

02

Conditions studied

  • Colorectal Adenoma
  • High Risk
  • TCM
03

In context

Lead sponsor

Jiangsu Famous Medical Technology Co., Ltd. is the lead sponsor of 20 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All of the following criteria must be met for enrolment:

  1. Aged 40-75 years, regardless of gender;
  2. High-quality colonoscopy performed within 14 days before randomisation, with initial endoscopic resection of all polyps and histological confirmation of at least one HR-CRA criteria;
  3. Complete endoscopic resection of every detected lesion;
  4. TCM syndrome differentiation of "spleen deficiency with dampness-heat";
  5. Signed and willingness to comply with long-term follow-up. a: High-quality colonoscopy criteria: Boston Bowel Preparation Scale score ≥ 6, cecal intubation confirmed by visualization of the ileocecal valve, and withdrawal time (excluding and polypectomy) ≥ 6 minutes.

Exclusion criteria

Exclusion Criteria:

Participants who meet any of the following criteria will be excluded from the trial:

  1. Concomitant or history of malignancy in the digestive system;
  2. Personal or family history of familial adenomatous polyposis or hereditary non-polyposis colorectal cancer (Lynch syndrome);
  3. History of inflammatory bowel disease;
  4. Malignancy in any other organ system within 5 years before screening, except for adequately treated thyroid carcinoma, cervical carcinoma in situ, basal or squamous cell skin carcinoma, or ductal carcinoma in situ of the breast cured by radical surgery;
  5. organic disorders or neuro-psychiatric conditions that may affect treatment or prognosis, including but not limited to severe cardiovascular or cerebrovascular disease, disease, motor, haematological, gastrointestinal, respiratory, immune, circulatory, reproductive, genitourinary, or endocrine disorders; coagulation abnormalities; or serious post-procedural complications (e.g., gastrointestinal bleeding, perforation, cholangitis, intra-abdominal infection, cardiorespiratory depression, mesenteric tear, or pneumoperitoneum), serum (AST) or alanine aminotransferase (ALT) >2.5 × the (ULN), or alkaline phosphatase (ALP) >2 × ULN;
  6. Active gastrointestinal disease, conditions predisposing to perforation, or disorders that could substantially interfere with the absorption, distribution, metabolism, or excretion of the drug, such as inability to take oral medication, uncontrolled nausea or vomiting, intestinal obstruction, or chronic diarrhoea;
  7. Within 3 months before screening, continuous use for ≥3 months of ≥2 doses per week (with \<2-week interruption) of agents potentially protective against colorectal adenoma: NSAIDs (e.g., aspirin, ibuprofen, celecoxib), metformin, berberine hydrochloride, folic acid, vitamin D, selenium, calcium, systemic immunotherapy, or Chinese patent medicines or decoctions labelled for "tonifying spleen and augmenting qi, clearing heat and eliminating dampness". Subjects may be enrolled after a of 1 month or ≥5 drug half-lives, whichever is longer;
  8. Cold-pattern manifestations such as aversion to cold, cold pain in the waist/abdomen, cold extremities, or preference for hot drinks;
  9. Pregnant or lactating women, or men and women of with plans to conceive during the trial or within 7 months after trial completion;
  10. Participation in another drug or device trial within 1 month or \< 5 half-lives of the investigational agent (whichever is longer) before screening, concurrent participation in another trial, or intention to participate in any other clinical trial during this trial;
  11. Known allergy or to ≥ 2 drugs or foods, or hypersensitivity to any component of the trial medication;
  12. Any other condition that, in the opinion of the investigator, makes the subject unsuitable for enrolment (e.g., poor expected compliance, cognitive impairment).
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
450 participants (estimated)

Study arms

  • Experimental
    Shenbai Granules

    Shenbai Granules is a traditional Chinese medicine preparation formulated from eight herbal ingredients, including Sophorae Flavescentis Radix (Kushen), Coptidis Rhizoma (Huanglian), and other herbs. It exerts therapeutic effects by clearing heat and drying dampness, while simultaneously invigorating the spleen and replenishing qi.

    Drug: Shenbai Granules

  • Placebo comparator
    Placebo

    The placebo was formulated using Shenbai Granules dry extract powder at 2% (w/w) of the equivalent dose found in the compound herbal granules, supplemented with colorants and flavoring agents to ensure visual and gustatory consistency with the Shenbai Granules.

    Drug: Placebo

Interventions

  • DrugShenbai Granules

    10 g/bag, two bags each time, twice a day, monthly for 30 days for 6 months.

    Also known as: Treatment group

  • DrugPlacebo

    10 g/bag, two bags each time, twice a day, monthly for 30 days for 6 months.

    Also known as: Control group

06

What researchers measure

Primary outcomes

  1. Cumulative detection rate of metachronous high-risk colorectal adenomas within 3 years after the first dose.

    The proportion of patients found to have metachronous high-risk colorectal adenomas during surveillance colonoscopy within 3 years after baseline adenoma resection. Colonoscopy will be performed in the first and third years.

    Time frame: 1, 3 years

Secondary outcomes

  1. Cumulative detection rate of metachronous low-risk colorectal adenomas within 3 years after the first dose.

    The proportion of patients found to have metachronous low-risk colorectal adenomas during surveillance colonoscopy within 3 years after baseline adenoma resection. Colonoscopy will be performed in the first and third years.

    Time frame: 1, 3 years

  2. Cumulative counts of metachronous colorectal adenomas detected within 3 years after the first dose.

    The cumulative counts of metachronous colorectal adenomas detected during colonoscopic surveillance within 3 years after baseline adenoma resection. Colonoscopy will be performed in the first and third years.

    Time frame: 1, 3 years

  3. The average number of metachronous colorectal adenomas detected within 3 years after the first dose.

    The average number of metachronous colorectal adenomas detected during colonoscopic surveillance within 3 years after baseline adenoma resection. Colonoscopy will be performed in the first and third years.

    Time frame: 1, 3 years

  4. Size of metachronous colorectal adenomas detected within 3 years after the first dose.

    The average size of metachronous colorectal adenomas detected during colonoscopic surveillance within 3 years after baseline adenoma resection. Colonoscopy will be performed in the first and third years.

    Time frame: 1, 3 years

  5. Location of metachronous colorectal adenomas detected within 3 years after the first dose.

    The location (left colon, right colon, rectum) of metachronous colorectal adenomas detected during colonoscopic surveillance within 3 years after baseline adenoma resection. Colonoscopy will be performed in the first and third years.

    Time frame: 1, 3 years

  6. Pathology of metachronous colorectal adenomas detected within 3 years after the first dose.

    The pathological types (histological architecture: tubular adenoma, villous adenoma, tubulovillous adenoma; and degree of dysplasia: high-grade intraepithelial neoplasia, low-grade intraepithelial neoplasia) of metachronous colorectal adenomas detected during colonoscopic surveillance within 3 years after baseline adenoma resection. Colonoscopy will be performed in the first and third years.

    Time frame: 1, 3 years

  7. Cumulative detection rate of serrated lesions within 3 years after the first dose.

    The proportion of cases with serrated lesions identified during colonoscopy surveillance within 3 years after baseline adenoma resection, relative to the total number of cases in the cohort. Colonoscopy will be performed in the first and third years.

    Time frame: 1, 3 years

  8. Cumulative incidence of serrated lesions detected within 3 years after the first dose.

    The cumulative incidence of serrated lesions detected during colonoscopic surveillance within 3 years after baseline adenoma resection. Colonoscopy will be performed in the first and third years.

    Time frame: 1, 3 years

  9. The average number of serrated lesions detected within 3 years after the first dose.

    The average number of serrated lesions detected during colonoscopic surveillance within 3 years after baseline adenoma resection. Colonoscopy will be performed in the first and third years.

    Time frame: 1, 3 years

  10. Size of serrated lesions detected within 3 years after the first dose.

    The average size of serrated lesions detected during colonoscopic surveillance within 3 years after baseline adenoma resection. Colonoscopy will be performed in the first and third years.

    Time frame: 1, 3 years

  11. Location of serrated lesions detected within 3 years after the first dose.

    The location distribution (left colon, right colon, rectum) of serrated lesions detected during colonoscopic surveillance within 3 years after baseline adenoma resection. Colonoscopy will be performed in the first and third years.

    Time frame: 1, 3 years

  12. Pathological types of all serrated lesions detected within 3 years after the first dose.

    The pathological types (colorectal serrated lesion, sessile serrated lesion, hyperplastic polyp) of serrated lesions will be detected during colonoscopic surveillance within 3 years after baseline adenoma resection. Colonoscopy will be performed in the first and third years.

    Time frame: 1, 3 years

  13. Incidence of colorectal cancer within 3 years after the first dose.

    The proportion of cases with interval colorectal cancer detected during surveillance colonoscopy within 3 years after baseline adenoma resection, relative to the total number of cases in the cohort. Colonoscopy will be performed in the first and third years.

    Time frame: 1, 3 years

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2025; primary completion for Nov 2028, 39 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2025
First posted
Aug 19, 2025
StartEst.
Aug 15, 2025
Primary completionEst.
Nov 30, 2028
CompletionEst.
Nov 30, 2028
Last update
Aug 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07129499
Lead sponsor
Jiangsu Famous Medical Technology Co., Ltd.
Collaborators
The First Affiliated Hospital with Nanjing Medical University, First Affiliated Hospital of Harbin Medical University, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing Traditional Chinese Medicine Hospital, The Second Hospital of Shandong University, Shengjing Hospital, Shenzhen Hospital of Southern Medical University, Sixth Affiliated Hospital, Sun Yat-sen University, Sichuan Provincial People's Hospital, Shanxi Provincial People's Hospital, Affiliated Hospital of Nanjing University of Chinese Medicine, RenJi Hospital
Responsible party
Sponsor
First posted
Aug 19, 2025
Start date
Aug 15, 2025 (estimated)
Primary completion
Nov 30, 2028 (estimated)
Completion
Nov 30, 2028 (estimated)
Last update
Aug 19, 2025

Study contacts

Haibo Cheng, Professor
Contact
hbcheng@njucm.edu.cn
025-85811001

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion